Article Text

Download PDFPDF

1315 MVdeltaC, a new therapeutic vaccine demonstrates promising preclinical immuno-oncolytic activities
  1. Aleksandr Barinov1,
  2. Chantal Combredet2,
  3. Claude Ruffié2,
  4. Valérie Najburg2,
  5. Nicolas Boisgerault3,
  6. Marc Gregoire1,
  7. Véronique Riebbels1,
  8. Jean-François Le Bigot1 and
  9. Frederic Tangy1
  1. 1Oncovita, Paris, France
  2. 2Institut Pasteur, Paris, France
  3. 3Inserm, Nantes, France


Background Oncovita, a biotech company spin-off from Institut Pasteur, is developing a therapeutic vaccine in oncology based on Measovir®, a proprietary technology derived from the safe and highly immunogenic measles attenuated vaccine virus (MV). MV is a paramyxovirus with a negative strand RNA genome. The MV specific tropism for cancer cells is due to the overexpression of its entry receptor CD46 on the surface of most cancer cells.

Methods We constructed MVdeltaC, a genetically modified MV by deletion of its virulence factor C. We evaluated its immuno-oncolytic activity in vitro on over 40 human tumoral cell lines, including mesothelioma, lung adenocarcinoma, bladder, ovarian, cervical cancer and hepatocarcinoma, and in vivo by i.p. or i.t. administration in different patient-derived xenograft (PDX) mesothelioma and bladder models, and finally in a syngeneic model of neuroblastoma in immunocompetent A/J mice. The mode of action (MOA) has been investigated ex vivo using human primary immune cells.

Results in vitro, MVdeltaC exhibited a strong oncolytic capacity which was 2 to 3 times greater than standard MV against a series of human tumor cell lines. MVdeltaC was active in more than 70% of the tested cell lines. In vivo, a single low dose given intraperitoneally in NOD/SCID mice grafted with human malignant mesothelioma induced a strong reduction of tumor mass two weeks after treatment. This potential was confirmed in PDX models of mesothelioma and bladder tumors by weekly administration of MVdeltaC. Finally, in immunocompetent A/J mice, only three i.t. administrations resulted in tumor regression and even total disappearance in 66% of mice. The animals that completely rejected the tumors were re-challenged on the other flank 3 months later with the same amount of tumor cells. No tumor growth was observed, suggesting an immune protection. In ex-vivo MOA experiments with human autologous primary cells, we demonstrated that the infection of cancer cells by MVdeltaC triggers the release of danger signals and tumor associated antigens (TAA), activation of mDC and pDC, phagocytosis of dying cancer cells and cross-presentation of TAA to autologous T lymphocytes.

Conclusions MVdeltaC demonstrated a very efficient immuno-oncolytic activity. Based on these promising preclinical data, Oncovita plans to initiate a FIH trial in patients with solid tumors. The activity on CPI resistant tumors will be of particular interest to investigate. We have already improved the mode of production of genetically stable MVdeltaC.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.